Comprehensive Stock Comparison
Compare FibroGen, Inc. (FGEN) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CANF | -9.3% revenue growth vs FGEN's -36.7% |
| Quality / Margins | FGEN | -160.6% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs FGEN's 1.21 |
| Dividends | FGEN | 0.3% yield; 1-year raise streak; CANF pays no meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs FGEN's -26.5% |
| Efficiency (ROA) | FGEN | 157.4% ROA vs CANF's -114.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
FibroGen is a biopharmaceutical company focused on developing novel therapeutics for serious medical conditions like anemia and fibrotic diseases. It generates revenue primarily through collaboration agreements with major pharmaceutical partners — including Astellas and AstraZeneca — which provide upfront payments, milestone payments, and royalties on future sales. The company's competitive advantage lies in its expertise in hypoxia-inducible factor biology and connective tissue growth factor inhibition, which has produced two late-stage drug candidates with novel mechanisms of action.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FGEN leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). CANF leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
CANF and FGEN operate at a comparable scale, with $560,000 and -$118M in trailing revenue. Profitability is closely matched — net margins range from -160.6% (FGEN) to -15.7% (CANF). On growth, CANF holds the edge at -36.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | -$118M | $560,000 |
| EBITDAEarnings before interest/tax | -$123M | -$9M |
| Net IncomeAfter-tax profit | $216M | -$9M |
| Free Cash FlowCash after capex | -$17M | -$8M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -5.1% | -16.0% |
| Net MarginNet income ÷ Revenue | -160.6% | -15.7% |
| FCF MarginFCF ÷ Revenue | -4.7% | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -97.7% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.7% | +36.4% |
Valuation Metrics
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $585M | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $625M | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | -15.63x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 19.75x | 9999.00x |
| Price / BookPrice ÷ Book value/share | — | 6.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FGEN delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-2 for CANF. On the Piotroski fundamental quality scale (0–9), FGEN scores 2/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | +12.3% | -2.1% |
| ROA (TTM)Return on assets | +157.4% | -114.0% |
| ROICReturn on invested capital | — | -4.5% |
| ROCEReturn on capital employed | -104.8% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $40M | -$5M |
| Cash & Equiv.Liquid assets | $50M | $5M |
| Total DebtShort + long-term debt | $90M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | -20.28x | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in CANF five years ago would be worth $2,351 today (with dividends reinvested), compared to $59 for FGEN. Over the past 12 months, CANF leads with a +169.9% total return vs FGEN's -26.5%. The 3-year compound annual growth rate (CAGR) favors CANF at 20.6% vs FGEN's -76.2% — a key indicator of consistent wealth creation.
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | +2059.1% |
| 1-Year ReturnPast 12 months | -26.5% | +169.9% |
| 3-Year ReturnCumulative with dividends | -98.6% | +75.3% |
| 5-Year ReturnCumulative with dividends | -99.4% | -76.5% |
| 10-Year ReturnCumulative with dividends | -98.3% | -98.5% |
| CAGR (3Y)Annualised 3-year return | -76.2% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than FGEN's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs FGEN's 59.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 0.36x |
| 52-Week HighHighest price in past year | $12.60 | $4.93 |
| 52-Week LowLowest price in past year | $4.85 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +59.5% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 39.4 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 27K | 4.3M |
Analyst Outlook
Wall Street rates FGEN as "Hold" and CANF as "Buy". Consensus price targets imply 273.3% upside for FGEN (target: $28) vs 52.6% for CANF (target: $7). FGEN is the only dividend payer here at 0.30% yield — a key consideration for income-focused portfolios.
| Metric | FGENFibroGen, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $28.00 | $7.25 |
| # AnalystsCovering analysts | 14 | 4 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.02 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | 100 | 0.76 | -99.2% |
| Can-Fite BioPharma … (CANF) | 100 | 32.52 | -67.5% |
Can-Fite BioPharma … (CANF) returned -76% over 5 years vs FibroGen, Inc. (FGEN)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | $181M | $30M | -83.6% |
| Can-Fite BioPharma … (CANF) | $164717.00 | $674000.00 | +309.2% |
FibroGen, Inc.'s revenue grew from $181M (2015) to $30M (2024) — a -18.2% CAGR. Can-Fite BioPharma Ltd.'s revenue grew from $0M (2015) to $1M (2024) — a 16.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | -47.4% | -160.6% | -238.6% |
| Can-Fite BioPharma … (CANF) | -29.1% | -11.7% | +59.9% |
FibroGen, Inc.'s net margin went from -47% (2015) to -161% (2024). Can-Fite BioPharma Ltd.'s net margin went from -29% (2015) to -12% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | -1.42 | -0.48 | +66.2% |
| Can-Fite BioPharma … (CANF) | -81 | -1.08 | +98.7% |
FibroGen, Inc.'s EPS grew from $-1.42 (2015) to $-0.48 (2024). Can-Fite BioPharma Ltd.'s EPS grew from $-81.00 (2015) to $-1.08 (2024).
Chart 5Free Cash Flow — 5 Years
FibroGen, Inc. generated $-138M FCF in 2024 (-23% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
FGEN vs CANF: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is FGEN or CANF a better buy right now?
Analysts rate Can-Fite BioPharma Ltd. (CANF) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FGEN or CANF?
Over the past 5 years, Can-Fite BioPharma Ltd. (CANF) delivered a total return of -76.5%, compared to -99.4% for FibroGen, Inc. (FGEN). A $10,000 investment in CANF five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: FGEN returned -98.3% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FGEN or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus FibroGen, Inc.'s 1.21β — meaning FGEN is approximately 236% more volatile than CANF relative to the S&P 500.
04Which has better profit margins — FGEN or CANF?
FibroGen, Inc. (FGEN) is the more profitable company, earning -160.6% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps -160.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FGEN leads at -507.8% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — FGEN or CANF?
In this comparison, FGEN (0.3% yield) pays a dividend. CANF does not pay a meaningful dividend and should not be held primarily for income.
06Is FGEN or CANF better for a retirement portfolio?
For long-horizon retirement investors, Can-Fite BioPharma Ltd. (CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36)). Both have compounded well over 10 years (CANF: -98.5%, FGEN: -98.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between FGEN and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.